AbbVie announces positive Phase 3 CERVINO topline for etentamig
AbbVie said its Phase 3 CERVINO trial for investigational etentamig in relapsed/refractory multiple myeloma met both primary endpoints, with etentamig achieving higher objective response results in topline findings.
AbbVie on Thursday said topline results from the Phase 3 CERVINO trial of investigational etentamig in patients with relapsed/refractory multiple myeloma were positive. The study met both primary endpoints, with etentamig posting a significantly higher objective response rate and a significantly longer duration of response.